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Introduction
Continuous ambulatory peritoneal dialysis (CAPD) pa-
tients using conventional glucose-containing dialysates
(GD) reveal a high prevalence of hypokalemia
1-4). Spital
et al. documented that 36% of all CAPD patients had hypo-
kalemia, that about 20% of these patients received potas-
sium (K
+) supplement, and for the correction of acute hy-
pokalemia, a method using dialysate directly mixed with
K
+ was very safe and effective
3). Furthermore, in a recently
reported Chinese study, hypokalemia, represented in 20.3%
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of CAPD patients, could be an independent risk factor for
their survival
5).
7.5% icodextrin (ID), a new class of osmotic agents that
is an alternative non-glucose-containing dialysate, has now
been proven to be clinically useful in the fluid management
of peritoneal dialysis (PD) patients and has improved bio-
compatibility when compared to the traditional solutions
6-9). We evaluated differences in serum K
+ profiles and in-
fluencing factors related internal K
+ balance between GD
and ID in stable CAPD patients, and additionally the safety
and effectiveness of acute intraperitoneal K
+ load.
Subjects and Method
1. Subjects
We enrolled nine stable CAPD patients at Hanyang
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This study aimed to compare the increment in plasma potassium concentration ([K
+]) as well as the role
of internal K
+ balance for its changes following acute K
+ supplementation between conventional 2.5%
glucose (GD) and non-glucose containing dialysate (icodextrin, ID) in continuous ambulatory peritoneal
dialysis (CAPD) patients. A total of 9 stable CAPD patients (5 men and 4 women; age, 56±13 years; 7
type-2 diabetics and 2 non-diabetics) on daily 4 exchanges of 2 L of glucose dialysate underwent the 6-hr
dwell on fasting in the morning with 2 L of 2.5% glucose mixed with 20 mEq/L of KCl, and then the
same regimen was repeated with icodextrin after 1-wk interval. The degree of intraperitoneal absorption
was comparable, 65±2% in GD and 68±2% in ID, respectively (p=NS). However, despite the similar plasma
K
+ levels at the baseline of both regimens, its increment was significantly less in GD than ID, which was
accompanied by more marked increase in the calculated intracellular K
+ redistribution (68±3% vs. 52±3%,
p<0.05). The basal levels of insulin were similar between the GD and ID groups. However, the change,
checked up after 2 hours’ dwell, from the basal insulin levels was much lower on ID. ID with a lesser
degree of transcelluar K
+ shift by the decreased secretion of insulin is more effective than the conventional
glucose solution for acute K
+ repletion via dialysate during CAPD. Furthermore, these results suggested
that the role of insulin for the internal K
+ balance was intact even in type-2 diabetic patients on CAPD.
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University Guri Hospital. They only used 1.5% or 2.5%
glucose-containing peritoneal dialysate (GD, Dianeal
®,
Baxter Corporation, Chicago, Illinois, USA) 2 L regularly
exchanged 4 times per day and were prescribed a strict
low K
+ diet (0.8 mEq/kg/day) by a renal dietician for at
least 2 months. We excluded the patient who had received
oral hypoglycemic agents. This interventional study was
approved by the internal review board of Hanyang Univer-
sity Guri Hospital, and individual written consent was ob-
tained before the study.
2. Methods
All enrolled patients received a 6-hr dwell of 2 L of
2.5% GD mixed with 40 mEq (20 mEq/L) of potassium
chloride (KCl) on fasting in the morning. The same method
was repeated with ID dialysate after a one-week interval.
They stopped insulin therapy and -blockers on the day β
of the intraperitoneal K
+ load test.
Blood and peritoneal dialysate samplings were per-
formed just before dialysate inflow and right after dialysate
outflow in order to evaluate acute changes in serum K
+,
serum osmolality and neurohormones (including epine-
phrine, insulin, and aldosterone levels) after the peritoneal
K
+ loads. The total amounts of K
+ absorbed from K
+-mixed
dialysate during dialysis and of K
+ translocated into cells
were calculated by the equation (1) of Spital et al.
3).
(1) Calculated amount (%) of K
+ shifted to ICF = [(K
+
absorbed 0.2× BW× serum K Δ
+) ÷ K
+ absorbed]×100%
3)
ICF, intracellular fluid; BW, body weight
Plasma insulin and serum aldosterone levels were meas-
ured by radioimmunoassay (insulin kit by Eiken Co.,
Tokyo, Japan, and aldosterone kit by Abbot Laboratories,
Wiesbaden, Germany), plasma epinephrine by high-per-
formance liquid chromatography and electrochemical de-
tection with a Waters 460 electrochemical detector (Waters
Co., Milford, MA, USA), and serum osmolality with a
Vapor Pressure Osmometer (Wescor Inc., Logan, UT, USA).
3. Statistical analysis
SPSS 12.0.1 for Windows software was used for all stat-
istical analyses (SPSS Inc, Chicago, IL, USA). Descriptive
data are expressed as mean±SD. The comparison between
ID and GD was assessed by Wilcoxon Signed Ranks Test.
A p value<0.05 was defined as statistically significant.
Result
Nine CAPD patients at our hospital were enrolled in
this study. The causes of end stage renal disease (ESRD)
were type 2 diabetes mellitus (7/9) and chronic glomer-
ulonephritis (2/9). The duration of CAPD was 6.9±6.4
(2-23) months (mean±SD (range)). The body mass index
(BMI) was 26.6±2.9 (23.1-32.8). Normalized protein nitro-
gen appearance (nPNA) was 0.98±0.32 (0.74-1.47) g/day.
The demographics of study population are shown in Table
Table 1. Baseline Characteristics of Nine CAPD Patients
(5 male, 4 female; 7 type-2 diabetics, 2 chronic glome-
rulonephritis)
Mean±SD Range
Age (years)
Duration of dialysis (months)
Height (cm)
Body weight (kg)
Body mass index (kg/m
2)
Urine volume (mL/day)
Mean blood pressure (mmHg)
nPNA (g/kg/day)
Serum hemoglobin (g/dL)
Serum BUN (mg/dL)
Serum creatinine (mg/dL)
Serum albumin (g/dL)
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Serum total CO2 (mEq/L)
56.4±13.3
6.9±6.4
163.0±8.9
71.3±8.9
26.6±2.9
602±321
93.7±9.8
0.98±0.3
11.6±2.1
50.2±18.4
6.1±1.7
2.9±0.4
8.4±0.9
4.1±0.5
25.6±2.4
38-77
2-23
154-178
57.4-81.1
23.1-32.8
100-1200
83-110
0.7-1.7
8.0-15.4
26-91
4.0-9.1
2.4-3.6
7.5-10.1
3.1-4.8
21-29
CAPD; continuous ambulatory peritoneal dialysis; nPNA,
normalized protein nitrogen appearance; BUN, blood urea
nitrogen.
Table 2. Comparison of the Compositions of Icodextrin
and 2.5% Glucose Solution
　 Icodextrin 2.5% glucose solution
Dextrose (g/dL)
Icodextrin (g/dL)
Sodium (mEq/L)
Chloride (mEq/L)
Calcium (mg/dL)
Magnesium (mEq/L)
Lactate (mEq/L)
Osmolarity (mOsm/L)
pH
−
7.5
132
96
3.5
0.5
40
282-286
5.2
2.5
−
132
96
3.5
0.5
40
396
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1. The compositions of GD and ID used in this study are
shown in Table 2.
1. Changes of serum K
+ and insulin following
intraperitoneal K
+ load
Amount of intraperitoneal K
+ (40 mEq, 20 mEq/L) load,
in dailysate, was 0.54±0.37 (0.38-0.70) mEq/kg. On GD,
plasma [K
+] before and after intraperitoneal K
+ loads was
4.10±0.12 mEq/L and 4.53±0.13 mEq/L, respectively On
ID, plasma [K
+] before and after intraperitoneal K
+ loads
was 4.09±0.12 mEq/L and 4.73±0.12 mEq/L, respectively.
Thus the increment of plasma [K
+] was significantly higher
on ID (0.64±0.65 mEq/L on ID vs. 0.37±0.78 mEq/L on
GD, p<0.05, Table 3, Fig. 1). In seven CAPD patients with
type 2 diabetes mellitus, the increments of plasma [K
+]
were similar (0.64±0.84 mEq/L on ID vs 0.37±0.87 mEq/L
on GD, p<0.05, Fig. 1) to average increments of plasma
[K
+].
K
+ absorbed through peritoneum were 25±1 mEq (65±
Fig. 1. Comparison of increments in the plasma potassium con-
centrations ([K
+]) between Icodextrin and 2.5% glucose solution
following intraperitoneal administration of K
+ (20 mEq/L) in
CAPD patients (n=9). CAPD, continuous ambulatory peritoneal
dialysis.
Table 3. The Distribution of Plasma K
+ between Icodextrin and 2.5% Glucose Solution following Intraperitoneal
Administration of K
+ (20 mEq/L) in Nine CAPD Patients
Patients Cause of ESRD IP K
+ load
mEq/kg BW
PK0 I
(mEq/L)
PK0 G
(mEq/L)
PK6 I
(mEq/L)
PK6 G
(mEq/L)
C JW
S SK
K YY
L JB
K SB
J SH
K JC
B SJ
K MS
Type-2 DM
Type-2 DM
Type-2 DM
Type-2 DM
Type-2 DM
Type-2 DM
Type-2 DM
CGN
CGN
0.51
0.38
0.61
0.62
0.70
0.39
0.65
0.53
0.49
3.8
4.6
3.9
3.7
4.3
4.6
4.3
3.8
3.8
3.8
4.7
4.0
3.6
4.3
4.4
4.4
3.9
3.8
4.3
5.0
4.6
4.5
5.3
5.0
5.0
4.5
4.4
4.1
4.8
5.3
4.2
4.8
4.6
4.6
4.0
4.4
Mean±SEM 0.54±0.37 4.09±0.12 4.10±0.12 4.73±0.12 4.53±0.13
PK0 I, Plasma [K
+] before K
+ load in Icodextrin; PK0 G, Plasma [K
+] before K
+ load in 2.5% glucose solution; PK6 I, Plasma
[K
+] 6-hr after K
+ load in Icodextrin; PK6 G, Plasma [K
+] 6-hr after K
+ load in 2.5% glucose solution; CAPD, continuous
ambulatory peritoneal dialysis; ESRD, end stage renal disease; IP, intraperitoneal; BW, body weight; DM, diabetes mellitus; CGN,
chronic glomerulonephritis;
Fig. 2. Comparison of the absorbed K
+ between Icodextrin and
2.5% glucose solution following intraperitoneal administration of
K
+ (40 mEq in 2 L) in nine CAPD patients. CAPD, continuous
ambulatory peritoneal dialysis.28 Joo-Hark Yi et al. : Potassium Homeostasis in CAPD Patients
2%) in ID and 26±2 mEq (68±2%) (p=NS, Fig. 2) in GD,
but calculated K
+ moving in intracellular space was less
on ID (13±1 mEq (52±3%) vs. 18±2 mEq (68±3%) on
GD, p<0.05, Fig. 3).
After 6 hours’ dwell of intraperitoneal K
+ load, [K
+]
in dialysate outflow were 4.8±0.48 (4.0-5.4) mEq/L on ID
and 4.7±0.4 (4.1-5.4) mEq/L on GD. The ratios between
[K
+] in dialysate and in plasma were 1.1±0.1 on ID and
1.1±0.5 on GD, thus the ratios were a relative equilibrium
nearly close to 1.0.
The basal levels of insulin (18.3±3.8 U/ml on GD vs. μ
19.1±4.3 U/ml on ID) were similar between the GD and μ
ID groups. However, the insulin level, checked up after
2 hours’ dwell, were 17.7±4.0 U/ml on ID vs. 30.9±6.0 μ
U/mL on GD, thus the change from basal insulin levels μ
was much lower on ID (-1.5±0.6 U/ml on ID vs. 12.6±2.6 μ
U/mL on GD, p<0.05, Fig. 4). In seven diabetic CAPD μ
patients, similar results were shown that the change from
basal insulin was also lower on ID (-1.5±0.6 U/ml on μ
ID vs. 11.1±3.1 U/mL on GD, p<0.05, Fig. 4). μ
Changes of blood aldosterone, epinephrine, and osmo-
lality from baseline levels were not significantly different
through the 6-hr dwell in both regimens of GD and ID
(Table 4).
2. Complications following intraperitoneal K
+ load
All subjects did not complain any symptoms and signs
and also their vital signs were stable after intraperitoneal
K
+ (40 mEq, 20 mEq/L) load.
Discussion
Generally, K
+ homeostasis is controlled by external and
internal K
+ balance. External K
+ balance is maintained be-
tween K
+ intake and excretion through the kidney and
intestine. Internal K
+ balance is affected by K
+ redistri-
bution between intracellular and extracellular spaces.
However, in ESRD, K
+ excretion through kidney reduces,
thus, K
+ homeostasis is maintained by low K
+ diet, K
+
Fig. 4. Comparison of changes in the plasma insulin levels
between Icodextrin and 2.5% glucose solution at 2-hr dwell
following intraperitoneal administration of potassium in CAPD
patients (n=9). CAPD, continuous ambulatory peritoneal dialysis.
Fig. 3. Comparison of the translocated K
+ to intracellular fluid
between Icodextrin and 2.5% glucose solution following intra-
peritoneal administration of K
+ (40 mEq in 2 L) in CAPD patients
(n=9). CAPD, continuous ambulatory peritoneal dialysis.
Table 4. Comparison of Changes in the Plasma Aldosterone,
Epinephrine and Osmolarity between Icodextrin and 2.5%
Glucose Solution following Intraperitoneal Administration of
Potassium (20 mEq/L) in Nine CAPD Patients
Time Icodextrin
(Mean±SEM)
2.5% glucose
(Mean±SEM) p
Aldosterone
(ng/dL)
Epinephrine
(pg/dL)
Osmolarity
(mOsm/KgH2O)
0-hr
6-hr
0-hr
6-hr
0-hr
6-hr
13.3±8.4
6.4±1.9
47.4±11.1
39.8±8.3
299.7±1.9
302.7±2.2
13.8±7.9
17.7±10.8
34.9±6.7
47.4±10.6
300.9±2.4
304.8±2.0
NS
NS
NS
NS
NS
NS
NS, not significantJoo-Hark Yi et al. : Potassium Homeostasis in CAPD Patients 29
removal by dialysis and intestine, and internal balance
10).
Especially, K
+ removal in PD occurs by dialysate and ultra-
filtrate amounts, exchange times per day, and average plas-
ma [K
+] level
10, 11). Theoretically it would not be enough
to maintain a safe plasma K
+ level because daily K
+ intake
is greater than daily K
+ removal through PD and excretion
via the intestine
1, 10). However, actually, in PD patients,
normokalemia and mild hypokalemia are more frequent
than hyperkalemia
1-4). Why does that phenomenon occur?
The answers are that K
+ moves in intracellular space as
glucose containing dialysate stimulates insulin secretion
and intracellular and intramuscular Kv levels are higher
in PD patients than in HD patients
12). Thus, internal K
+
balance, so called K
+ redistribution, could play a role to
maintain K
+ homeostasis in PD.
After acute peritoneal K
+ load, K
+ absorption rates
through the peritoneum were similar between ID and GD
(65±2% vs. 68±2%), However Spital et al. reported that
K
+ absorption rates through the peritoneum were 73%
3).
The difference of absorption rates can be explained by the
residual renal K
+ excretion that might slightly remain in
our study population because the average urine volume was
602 mL/day. Plasma [K
+] increment was significantly high-
er in ID than GD after K
+ load and the increment of insulin
was significantly lower in ID than GD. Thus glucose con-
taining dialysate could induce insulin secretion that caused
K
+ redistribution toward intracellular space.
Furthermore, a noticeable point is that internal K
+ bal-
ance for K
+ homeostasis could be intact in diabetic ESRD
patients who have insulin resistance and impairment of in-
sulin secretion
3). A previous study by Tzamalouksa et al.
has shown that the frequency and causes for plasma [K
+]
disturbances are similar between diabetic and nondiabetic
dialysis patients
10). A critical limitation of this study is that
the size of our study population was not large enough to
compare the difference between diabetic and nondiabetic
PD patients, the result of seven diabetic PD patients in
our study has shown that the increment of insulin was sig-
nificantly higher in GD than ID, after K
+ load. Such results
represented that insulin, also in diabetic ESRD patients,
could play a role to control internal K
+ balance.
As mentioned above, the long term use of high-glucose
containing dialysate could provoke peritoneal damage and
insulin secretion that causes hyperinsulinemia or athero-
sclerotic cardiovascular accidents
13). On the other hand, ID,
as iso-osmolar and starch-derived glucose polymer, reduces
hyperinsulinemia, insulin resistance
13), and glucose degra-
dation product (GDP) which material causes the peritoneal
damage by the stimulation of mesothelial cell apoptosis
and oncosis in peritoneum
14). One study reported that the
long term use of ID does not cause weight gain and ede-
ma
15). Thus ID is expected to substitute for GD in hypo-
kalemic PD patients due to lower peritoneal damage and
lower K
+ shift to intracellular space than GD.
In conclusion, we suggest that intraperitoneal K
+ load
and using ID to substitute for GD, as the treatment for
acute hypokalemia in CAPD patient, could be safe and
effective methods because ID less stimulates insulin secre-
tion than GD. K
+ homeostasis, in diabetic CAPD patients,
could be well controlled without defects of internal K
+ bal-
ance, so called K
+ redistribution, in this study.
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